Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2017 Filed Aug 28, 2017 16:06 UTC |
OLEARY DENISE MDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,010 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0001127602-17-026536 · form4.xml · derivative · entry 2 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,010 shares Expires 2017-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 1,010 New Medtronic ordinary shares for $52.84 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,010 Medtronic common stock shares for $52.84 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| August 25, 2017 Filed Aug 28, 2017 16:06 UTC |
OLEARY DENISE MDirector
|
Exercise / conversionOrdinary Shares | 1,010 | $52.84 | $53,368.40 |
DisclosureSEC source: 0001127602-17-026536 · form4.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 171 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:01 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GiftOrdinary Shares | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026511 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · GRAT Disclosed balance after: 12,195 Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:01 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GiftOrdinary Shares | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026511 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,503 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 18:59 UTC |
Hanson Bryan CEVP, President, MITG
|
Tax withholdingOrdinary Shares | 11,358 | $83.52 | $948,620.16 |
DisclosureSEC source: 0001127602-17-024712 · form4.xml · nonDerivative · entry 2 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,555 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:55 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024705 · form4.xml · derivative · entry 4 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:55 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 34,934 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024705 · form4.xml · derivative · entry 3 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,934 Underlying: Ordinary Shares · 34,934 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:55 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantOrdinary Shares | 8,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024705 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,215 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:53 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 65,103 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024704 · form4.xml · derivative · entry 5 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,103 Underlying: Ordinary Shares · 65,103 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:53 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024704 · form4.xml · derivative · entry 4 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:53 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantOrdinary Shares | 16,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024704 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,469 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:05 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024715 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:05 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
GrantStock Option (Right to Buy) · Derivative | 41,285 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024715 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,285 Underlying: Ordinary Shares · 41,285 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:05 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
GrantOrdinary Shares | 10,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024715 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,945 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:03 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GrantStock Option (Right to Buy) · Derivative | 214,363 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024714 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,363 Underlying: Ordinary Shares · 214,363 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:03 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
GrantOrdinary Shares | 53,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024714 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,698 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:59 UTC |
Hanson Bryan CEVP, President, MITG
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024712 · form4.xml · derivative · entry 4 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:59 UTC |
Hanson Bryan CEVP, President, MITG
|
GrantStock Option (Right to Buy) · Derivative | 57,958 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024712 · form4.xml · derivative · entry 3 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,958 Underlying: Ordinary Shares · 57,958 shares Expires 2027-07-31 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:59 UTC |
Hanson Bryan CEVP, President, MITG
|
GrantOrdinary Shares | 14,490 | $83.97 | $1,216,725.30 |
DisclosureSEC source: 0001127602-17-024712 · form4.xml · nonDerivative · entry 1 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,913 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 511 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:56 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024708 · form4.xml · derivative · entry 3 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:56 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 53,988 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024708 · form4.xml · derivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,988 Underlying: Ordinary Shares · 53,988 shares Expires 2027-07-31 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:56 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantOrdinary Shares | 13,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024708 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,530 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 252 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:00 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024713 · form4.xml · derivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:00 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 47,637 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024713 · form4.xml · derivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,637 Underlying: Ordinary Shares · 47,637 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:00 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantOrdinary Shares | 11,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024713 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,960 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:58 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024710 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:58 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 39,697 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024710 · form4.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,697 Underlying: Ordinary Shares · 39,697 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 18:58 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantOrdinary Shares | 9,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024710 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,831 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:53 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024703 · form4.xml · derivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:53 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 36,521 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024703 · form4.xml · derivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,521 Underlying: Ordinary Shares · 36,521 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:53 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantOrdinary Shares | 9,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024703 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,426 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:56 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024707 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:56 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantStock Option (Right to Buy) · Derivative | 38,109 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024707 · form4.xml · derivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,109 Underlying: Ordinary Shares · 38,109 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 14:56 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantOrdinary Shares | 9,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024707 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,473 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 12:34 UTC |
Surface Carol ASVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 3,872 | $84.29 | $326,370.88 |
DisclosureSEC source: 0001127602-17-024464 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,481 F1 · balance_after: This balance has increased by 1007 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:47 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
Tax withholdingOrdinary Shares | 7,270 | $84.29 | $612,788.30 |
DisclosureSEC source: 0001127602-17-024472 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,193 F1 · balance_after: This balance increased by 1,994 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:43 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
Tax withholdingOrdinary Shares | 4,621 | $84.29 | $389,504.09 |
DisclosureSEC source: 0001127602-17-024470 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,623 F1 · balance_after: This balance increased by 1159 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:38 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
Tax withholdingOrdinary Shares | 28,522 | $84.29 | $2,404,119.38 |
DisclosureSEC source: 0001127602-17-024467 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,107 F1 · balance_after: This balance increased by 5013 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:36 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Tax withholdingOrdinary Shares | 5,094 | $84.29 | $429,373.26 |
DisclosureSEC source: 0001127602-17-024466 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,050 F1 · balance_after: This balance increased by 1063 shares due to exempt transactions such as dividend reinvestment and ESPP. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:42 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
Tax withholdingOrdinary Shares | 3,532 | $84.29 | $297,712.28 |
DisclosureSEC source: 0001127602-17-024469 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,906 F1 · balance_after: This balance increased by 812 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 12:40 UTC |
TEN HOEDT ROBEVP & President EMEA
|
Tax withholdingOrdinary Shares | 330 | $84.29 | $27,815.70 |
DisclosureSEC source: 0001127602-17-024468 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,295 F1 · balance_after: This balance increased by 387 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 12:45 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Tax withholdingOrdinary Shares | 3,914 | $84.29 | $329,911.06 |
DisclosureSEC source: 0001127602-17-024471 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,945 F1 · balance_after: This balance increased by 930 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 20:28 UTC |
Hanson Bryan CEVP, President, MITG
|
SaleOrdinary Shares | 12,000 | $88.57 | $1,062,840.00 |
DisclosureSEC source: 0001127602-17-023783 · form4.xml · nonDerivative · entry 1 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,912 F1 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased 509 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 15:16 UTC |
Lenehan James TDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,010 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0001127602-17-023489 · form4.xml · derivative · entry 2 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,010 shares Expires 2017-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option to purchase 1,010 New Medtronic ordinary shares for $52.84 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,010 Medtronic common stock shares for $52.84 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 15:16 UTC |
Lenehan James TDirector
|
Exercise / conversionOrdinary Shares | 1,010 | $52.84 | $53,368.40 |
DisclosureSEC source: 0001127602-17-023489 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2017 Filed Jun 21, 2017 21:14 UTC |
ANDERSON RICHARD HDirector
|
PurchaseOrdinary Shares | 5,600 | $88.90 | $497,840.00 |
DisclosureSEC source: 0001127602-17-022010 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,910 F1 · price: The price reported is the weighted average price. Shares were purchased in multiple transactions at prices ranging from $88.895 to $88.9006. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:09 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
Tax withholdingOrdinary Shares | 7,047 | $88.82 | $625,914.54 |
DisclosureSEC source: 0001127602-17-022008 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,781 F1 · balance_after: This balance increased by 1,039 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 17:48 UTC |
POZEN ROBERT CDirector
|
Tax withholdingOrdinary Shares | 628 | $87.65 | $55,044.20 |
DisclosureSEC source: 0001127602-17-021523 · form4.xml · nonDerivative · entry 1 POZEN ROBERT C · CIK 0001278408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,987 Read SEC document |
| May 26, 2017 Filed May 31, 2017 16:28 UTC |
Lenehan James TDirector
|
Tax withholdingOrdinary Shares | 647 | $85.09 | $55,053.23 |
DisclosureSEC source: 0001127602-17-019836 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,343 Read SEC document |
| May 02, 2017 Filed May 4, 2017 14:20 UTC |
OLEARY DENISE MDirector
|
Tax withholdingOrdinary Shares | 650 | $84.75 | $55,087.50 |
DisclosureSEC source: 0001127602-17-016841 · form4.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,379 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.